The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide. "I ...

While the political pushback to ESG continues to grow in the U.S., there was little sign in Davos last week that business ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's U.S. patent expiration while projecting continued growth in 2025.

Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive Giovanni Caforio as ...

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public health funding are ...

Schaffert said: "Becoming CEO of Novartis Oncology is a great honour and I am humbled to be given the opportunity to lead one of the top-tier oncology businesses in the world.

The question is: Will the company take it? “We’re certainly watching the space,” Novartis CEO Vas Narasimhan, M.D., said of PD-1xVEGF bispecifics during a fourth-quarter earnings call with ...

Data for December were not yet available. Kisqali is undergoing “a very rapid launch” in early breast cancer, Novartis CEO Vas Narasimhan said during a media call Friday. As Narasimhan shared ...

FRANKFURT, Jan 31 (Reuters) - The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming ...